ArticleEJNMMI research2026
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundImage-based dosimetry of 225Ac is challenging due to its high cytotoxicity, which limits the administered dose and, consequently, restricts the number of photons available for imaging. This study aimed to estimate human equivalent dose of 225Ac-NOTA-trastuzumab while considering dose contribution from daughter radionuclides using mouse biodistribution of 64Cu-NOTA-trastuzumab by utilizing a combined model of mouse-to-human extrapolation and Bateman equation.
resultsResidence times estimated by methods M3, which involved mouse residence times and biological half-life allometry was significantly paired to human residence times. The proposed method demonstrated that the residence time of 225Ac and its progeny was very similar within the same organ. The highest residence time of 225Ac-NOTA-trastuzuamb was observed in liver, measuring 2.57 × 10− 2 MBq·h/MBq, while stomach exhibited the lowest residence time of 8.24 × 10− 4 MBq·h/MBq. The estimated effective dose of 225Ac-NOTA-trastuzumab was 6.64 × 10− 1 mSv/MBq.
conclusionsIn this study, we estimated human equivalent dose of 225Ac-NOTA-trastuzumab using preclinical data of 64Cu-NOTA-trastuzumab. Extrapolation method based on biological half-life allometry produced results consistent with clinical data. To account for dose contribution from daughter radionuclides, extrapolation method was corrected with the solution of Bateman equation. Our proposed method is capable of calculating the radiopharmaceutical’s residence time in human from preclinical distribution data while considering the contribution of daughter radionuclide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.